UNSPSC 51171809: Cyclizine

This classification denotes an antiemetic agent with the molecular formula C18H22N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QRW9FCR9P2, chemically known as piperazine, 1- (diphenylmethyl)-4-methyl-, monohydrochloride but generally known as cyclizine, which bears US NIH Compound Identifier 6726. European Medicines Agency schedules Cyclizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06847MIG. The term CYCLIZINE is an International Non-Proprietary Name.

UNSPSC 51171809 Cyclizine, a Commodity code, describes pharmaceutical products that state and local governments procure primarily through specimen-collection and drug-testing programs, cooperative purchasing agreements for multi-source generics and over-the-counter products, and emerging direct-to-manufacturer pharmacy initiatives. Recent state and local solicitations under this code reflect demand for urinalysis and alternative testing services (oral fluid, hair) used in criminal justice supervision, generic pharmaceutical supply through established wholesaler networks, and exploratory contracting models that bypass traditional pharmacy benefit managers. Collin County's Community Supervision and Corrections Department and the Texas Health and Human Services Commission represent the issuing bodies active under this code, alongside multi-state cooperative purchasing entities like the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which aggregates demand across state agencies and local facilities. The code captures both specimen-collection services bundled with laboratory testing and direct pharmaceutical supply agreements.

Activity under this code spans Texas and Minnesota, with MMCAP's cooperative purchasing vehicle extending across participating states including Oregon. The most prominent recent opportunity is Collin County's RFP 2026-327 for offender specimen collection and drug testing services, posted July 9, 2026, with proposals due July 23, 2026, seeking immunoassay and mass-spectrometry confirmation testing across two sites with an estimated annual volume of 25,031 tests and a contract value of $600,000 over two years with three optional one-year renewals. MMCAP's concurrent RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products, issued January 20, 2026, with a March 26, 2026 response deadline, requires vendors to supply products through three authorized wholesalers with pricing weighted 75 percent in evaluation and a two-year initial term. The Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, represents exploratory procurement aimed at establishing direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels, with no formal award values or timelines disclosed at the information-gathering stage.